8-K: SUNSHINE BIOPHARMA REPORTS 2024 SECOND QUARTER RESULTS: SECOND QTR REVENUES UP 67%, YTD REVENUES UP 61%
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.